Insights into the molecular basis of a bispecific antibody’s target selectivity

mAbs

Volumn 7, Issue 3, 2015, Pages 461-469

  Mazor, Yariv ^a   Hansen, Anna ^b   Yang, Chunning ^a   Chowdhury, Partha S ^a   Wang, Jihong ^b   Stephens, Geoffrey ^b   Wu, Herren ^a   Dall’Acqua, William F ^a  

^a MEDIMMUNE   (United States)

^b Department of Respiratory Inflammation and Autoimmunity MedImmune ^*  (United States)

Author keywords

Affinity; Avidity; B cells; Bispecific antibody; Bivalent; CD4; CD70; Monovalent; Selective targeting; T cells

Indexed keywords

BISPECIFIC ANTIBODY; CD4 ANTIBODY; IBALIZUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING KINETICS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MUTAGENESIS; RECEPTOR DENSITY; SIZE EXCLUSION CHROMATOGRAPHY; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PROCEDURES;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE DEPLETION;

EID: 84945195275     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1022695     Document Type: Article

References (27)

1. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6: 343-57; PMID: 16622479; http://dx. doi. org/10. 1038/nri1837.
2. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9: 767-74; PMID: 20811384; http://dx. doi. org/10. 1038/nrd3229.
3. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012; 17: 954-63; PMID: 22561895; http://dx. doi. org/10. 1016/j. drudis. 2012. 04. 006.
4. Reichert JM. Antibodies to watch in 2014. mAbs 2014; 6: 5-14; http://dx. doi. org/10. 4161/mabs. 27333.
5. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25: 1290-7; PMID: 17934452; http://dx. doi. org/10. 1038/nbt1345.
6. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008; 15: 422-32; PMID: 18288997; http://dx. doi. org/10. 2174/092986708783503 212.
7. Alexander S, Friedl P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol Med 2012; 18: 13-26; PMID: 22177734; http://dx. doi. org/10. 1016/j. molmed. 2011. 11. 003.
8. Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther 2010; 12: 176-83; PMID: 20373261.
9. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4: 182-97; PMID: 22453100; http://dx. doi. org/10. 4161/mabs. 4. 2. 19000.
10. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-16; PMID: 20414204; http://dx. doi. org/10. 1038/nri2761.
11. Marvin JS, Zhu Z. Recombinant approaches to IgGlike bispecific antibodies. Acta Pharmacol Sin 2005; 26: 649-58; PMID: 15916729; http://dx. doi. org/10. 1111/j. 1745-7254. 2005. 00119. x.
12. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 2010; 12: 340-9; PMID: 20521223.
13. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulinlike growth factor receptor demonstrates superior antitumor activity. MAbs 2011; 3: 273-88; PMID: 21393993; http://dx. doi. org/10. 4161/mabs. 3. 3. 15188.
14. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009; 24: 155-61; PMID: 19409036; http://dx. doi. org/10. 1089/cbr. 2009. 0627.
15. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280: 19665-72; PMID: 15757893; http://dx. doi. org/10. 1074/jbc. M500815200.
16. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99: 1415-25; PMID: 18841159; http://dx. doi. org/10. 1038/sj. bjc. 6604700.
17. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11: 582-93; PMID: 22248472; http://dx. doi. org/10. 1158/1535-7163. MCT-11-0820.
18. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, Chisholm P. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992; 149: 1779-87; PMID: 1380539.
19. Terrett JA, Lu L, King DJ, Cardarelli JM, Pan C, Huang H, Coccia MA. Human monoclonal antibodies to CD70. WO2007038637A2 2006. Available at: https://www. google. com/patents/WO2007038637A2.
20. Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bi-specific IgG design. MAbs 2015; in press; PMID: 25621507.
21. FreemanMM, SeamanMS, Rits-Volloch S, Hong X, Kao CY, HoDD, Chen B. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure 2010; 18: 1632-41; PMID: 21134642; http://dx. doi. org/10. 1016/j. str. 2010. 09. 017.
22. Pack P, Muller K, Zahn R, Pluckthun A. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J Mol Biol 1995; 246: 28-34; PMID: 7853401; http://dx. doi. org/10. 1006/jmbi. 1994. 0062.
23. Muller KM, Arndt KM, Pluckthun A. A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett 1998; 432: 45-9; PMID: 9710248; http://dx. doi. org/10. 1016/S0014-5793(98)00829-1.
24. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12: 278-87; PMID: 22437872; http://dx. doi. org/10. 1038/nrc3236.
25. Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol 2008; 20: 276-85; PMID: 18684640; http://dx. doi. org/10. 1016/j. smim. 2008. 07. 001.
26. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393: 672-92; PMID: 19699208; http://dx. doi. org/10. 1016/j. jmb. 2009. 08. 032.
27. Parekh BS, Berger E, Sibley S, Cahya S, Xiao L, LaCerte MA, Vaillancourt P, Wooden S, Gately D. Development and validation of an antibody-dependent cellmediated cytotoxicity-reporter gene assay. MAbs 2012; 4: 310-18; PMID: 22531445; http://dx. doi. org/10. 4161/mabs. 19873.